<?xml version='1.0' encoding='utf-8'?>
<document id="22329518"><sentence text="Human immunodeficiency virus-associated malignancies: a therapeutic update." /><sentence text="Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies" /><sentence text=" Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people" /><sentence text=" Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers" /><sentence text=" As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach" /><sentence text=" Consistently, procedures that have been so far precluded to HIV+ subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population" /><sentence text=" Which also would mean a full removal of the stigma which has weighed on it" /><sentence text=" Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist" /><sentence text=" Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4+ cells &gt; 500/Î¼l" /><sentence text=" In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology" /><sentence text="" /></document>